NEW YORK – Guardant Health announced Tuesday that its Guardant Reveal liquid biopsy test has received coverage from Medicare administrative contractor Palmetto GBA to monitor colorectal cancer ...

Shares of Guardant Health (NASDAQ:GH) have increased by 5.0% in premarket trading Tuesday following the company's ...

The test was previously covered for use in colorectal cancer patients in the early post-surgical setting only.

Guardant Health has secured Medicare coverage from Palmetto for its blood test to monitor for disease recurrence in patients with colorectal cancer.

MADISON, Wis. - Exact Sciences Corp. (NASDAQ:EXAS), a leader in cancer screening and diagnostic tests with a market capitalization of $10 billion, announced clinical validation data for its ...

President Trump rescinded an executive order that prompted the creation of three Medicare drug-pricing experiments ...

President Trump's inaugural address to the nation on Monday contained few references to healthcare, but the health topics he ...

But when her lung collapsed again years later, she had Medicaid coverage. Wynn was admitted to the hospital, received ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that the first set of abstracts have been released from several studies that will be shared at the ...